Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kerry Moose

Nurse Practitioner Washington, DC Nurse Practitioner

NPI 1366748931 CMS profile 11061344

3800 Reservoir Rd Nw, Washington, DC 20007

Open in the dashboard

General payments

$1,707

43 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerry Moose of Washington, DC is reported in the CMS Open Payments database as having received $1,707 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $144 4
2024 General $886 11
2023 General $343 12
2022 General $187 9
2021 General $146 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerry Moose
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kerry Moose were reported at $144. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kerry Moose Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $146 $135 $40–$426 $132
2022 $187 $152 $48–$470 $149
2023 $343 $166 $54–$529 $160
2024 $886 $173 $55–$556 $164
2025 $144 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Integra LifeSciences Corporation $839 11 payments
  2. Smith+Nephew, Inc. $282 13 payments
  3. PolyNovo North America LLC $174 2 payments
  4. Organogenesis Inc. $147 7 payments
  5. Next Science LLC $112 2 payments
  6. Bone Support Inc. $44 1 payment
  7. Tactile Systems Technology Inc $29 2 payments
  8. MIMEDX Group, Inc. $22 1 payment
  9. Melinta Therapeutics, Inc. $15 1 payment
  10. Avita Medical Americas, LLC $15 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,198 40 payments
  2. Long term medical supply or device loan $509 3 payments
Products named General payments · program years 2021–2025
  1. Integra Recon-Skin And Wound $546 7 payments
  2. INTEGRA DERMAL REGENERATION TEMPLATE $311 7 payments
  3. PRIMATRIX $311 7 payments
  4. Integra Recon-Skin And Wound $285 6 payments
  5. Integra Recon-Skin And Wound $285 6 payments
  6. ACell $247 2 payments
  7. GRAFIX PL $192 8 payments
  8. NOVOSORB BTM $174 2 payments
  9. Puraply $126 6 payments
  10. SurgX $112 2 payments
  11. Other $889 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

101

Median for Nurse Practitioner: 389

Drug cost

$2,085

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 25 $884
Ammonium Lactate Generic 33 $732
Doxycycline Hyclate Generic 26 $354
Triamcinolone Acetonide Generic 17 $114

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$21,848

Medicare's payments for the services billed

Medicare patients

177

Average age 74

Services billed

429

111 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 47%
Chronic kidney disease 43%
Heart failure 38%
Ischemic heart disease 37%
Atrial fibrillation 29%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record